{"generic":"Phenytoin","drugs":["Dilantin","Dilantin Infatabs","Dilantin-125","Phenytoin"],"mono":{"0":{"id":"465045-s-0","title":"Generic Names","mono":"Phenytoin"},"1":{"id":"465045-s-1","title":"Dosing and Indications","sub":[{"id":"465045-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Patients at risk of seizure, oral loading dose:<\/b> (Extended-release capsules) For men, 18.7 mg\/kg ORALLY once; for women, 24.8 mg\/kg ORALLY once; begin oral maintenance dose 24 hours after oral loading dose (study dose)<\/li><li><b>Patients at risk of seizure, oral loading dose:<\/b> (Immediate-release capsules) 6 mg\/kg ORALLY every 3 hours for 3 doses totalling 18 mg\/kg (study dose)<\/li><li><b>Patients at risk of seizure, oral loading dose:<\/b> (Tablets) 20 mg\/kg ORALLY in divided doses with two-thirds of dose followed by one-third of dose 2 hours later; for weight less than 60 kg, minimum dose is 1200 mg; for weight greater than 80 kg, MAX dose is 1600 mg; if no nystagmus present at 24 hours, give 100 mg ORALLY at 24 hours and 36 hours and begin 100 mg ORALLY 3 times daily at 48 hours after loading dose; if terminal nystagmus present at 24 hours, give 100 mg ORALLY at 24 hours and begin 100 mg ORALLY 3 times daily at 48 hours after loading dose; if clinical nystagmus present at 24 hours, begin 100 mg ORALLY 3 times daily at 48 hours after loading dose (study dose)<\/li><li><b>Seizure, During and following neurosurgery; Treatment and Prophylaxis:<\/b> (Oral tablets (Infatabs(R)) 100 mg (2 tablets) 3 times daily, usual maintenance dose 300 to 400 mg\/day (MAX dose 600 mg\/day)<\/li><li><b>Seizure, Generalized Tonic-Clonic and Complex Partial (psychomotor and temporal lobe) Seizures:<\/b> (Oral suspension) 125 mg (5 mL) ORALLY 3 times daily; adjust dose every 7 to 10 days as necessary (MAX dose 625 mg\/day)<\/li><li><b>Seizure, Generalized Tonic-Clonic and Complex Partial (psychomotor and temporal lobe) Seizures:<\/b> (Oral tablets (Infatabs(R)) 100 mg (2 tablets) ORALLY 3 times daily, usual maintenance dose 300 to 400 mg\/day (MAX dose 600 mg\/day)<\/li><\/ul>"},{"id":"465045-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Children over 6 years old and adolescents may require the minimum adult dose (300 mg\/day)<\/li><li><b>Seizure, During and following neurosurgery; Treatment and Prophylaxis:<\/b> (Oral tablets (Infatabs(R): 5 mg\/kg\/day divided equally into 2 or 3 doses to a subsequent maximum of 300 mg\/day; usual maintenance dose is 4 to 8 mg\/kg\/day; children over the age of 6 years may require minimum adult dose (300 mg\/day)<\/li><li><b>Seizure, Generalized Tonic-Clonic and Complex Partial (psychomotor and temporal lobe) Seizures:<\/b> (Oral suspension or oral tablets (Infatabs(R)) 5 mg\/kg\/day divided equally into 2 or 3 doses to a subsequent maximum of 300 mg\/day; usual maintenance dose is 4 to 8 mg\/kg\/day; children over the age of 6 years may require minimum adult dose (300 mg\/day)<\/li><\/ul>"},{"id":"465045-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>geriatrics:<\/b> initially 3 mg\/kg\/day, in divided doses, the dosage being adjusted according to serum hydantoin concentrations and patient response<\/li><li><b>hypoalbuminemia:<\/b> (normalized phenytoin concentration in hypoalbuminemic patients) normal serum phenytoin concentration in non-hypoalbuminemic patients = observed serum phenytoin concentration in hypoalbuminemic patients divided by 0.25 times albumin concentration plus 0.1<\/li><li><b>liver disease:<\/b> there may be an increase in unbound phenytoin concentrations in patients with hepatic insufficiency, measuring unbound phenytoin concentrations may be useful in these patients<\/li><li><b>pregnancy:<\/b> phenytoin requirements are greater during pregnancy, requiring increases in doses in some patients. After delivery, the dose should be decreased to avoid toxicity<\/li><li><b>renal impairment:<\/b> there may be an increase in unbound phenytoin concentrations in patients with renal disease, measuring unbound phenytoin concentrations may be useful in these patients<\/li><\/ul>"},{"id":"465045-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Seizure, During and following neurosurgery; Treatment and Prophylaxis<\/li><li>Seizure, Generalized Tonic-Clonic and Complex Partial (psychomotor and temporal lobe) Seizures<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Decubitus ulcer<\/li><li>Eclampsia - Seizure<\/li><li>Pain, chronic<\/li><li>Pre-eclampsia - Seizure<\/li><li>Wound healing<\/li><\/ul>"}]},"3":{"id":"465045-s-3","title":"Contraindications\/Warnings","sub":[{"id":"465045-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant use with delavirdine<\/li><li>concomitant use with rilpivirine<\/li><li>hypersensitivity to phenytoin, other product components, or other hydantoins<\/li><\/ul>"},{"id":"465045-s-3-10","title":"Precautions","mono":"<ul><li>Dermatologic:<\/li><li>-- serious and potentially fatal dermatologic reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported; discontinuation may be required<\/li><li>-- HLA-B*1502-positive patients, most commonly Asians including South Asian Indians, are at greater risk for Stevens-Johnson syndrome and toxic epidermal necrolysis; avoid using as an alternative for carbamazepine in patients testing positive for this al&le;<\/li><li>-- skin rash may occur; discontinue upon occurrence and evaluate, however possible permanent discontinuation may be required<\/li><li>Endocrine and Metabolic:<\/li><li>-- hyperglycemia has been reported; use caution in patients with diabetes mellitus<\/li><li>Hematologic:<\/li><li>-- hematopoietic events, including thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression, including fatal cases, have been reported<\/li><li>-- hypoalbuminemia may increase fraction of unbound phenytoin; interpret total phenytoin plasma concentrations with caution<\/li><li>-- porphyria may be exacerbated<\/li><li>Hepatic:<\/li><li>-- hepatotoxicity, including jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, eosinophilia, and acute hepatic failure, with some fatal cases, have been reported; discontinuation may be required<\/li><li>-- hepatic disease may increase fraction of unbound phenytoin; interpret total phenytoin plasma concentrations with caution<\/li><li>-- liver function impairment may result in phenytoin toxicity<\/li><li>Immunologic:<\/li><li>-- drug reaction with eosinophilia and systemic symptoms (DRESS)\/multiorgan hypersensitivity, including fatal cases, has been reported; evaluate early signs\/symptoms and discontinue if confirmed<\/li><li>-- consider alternative antiseizure therapy in cases of personal or immediate family history of hypersensitivity to structurally similar drugs such as carboxamides (eg, carbamazepine), barbiturates, succinimides, and oxazolidinediones (eg, trimethadione)<\/li><li>Musculoskeletal:<\/li><li>-- bone density decrease (osteopenia, osteoporosis, osteomalacia) and fractures may occur with chronic use due to enhanced vitamin D metabolism leading to vitamin D deficiency, hypocalcemia, and hypophosphatemia; monitor and treat as appropriate<\/li><li>Neurologic:<\/li><li>-- abrupt withdrawal should be avoided due to the potential for status epilepticus; discontinue gradually when possible<\/li><li>Psychiatric:<\/li><li>-- increased risk of suicidality; monitoring recommended<\/li><li>Renal:<\/li><li>-- renal disease may increase fraction of unbound phenytoin; interpret total phenytoin plasma concentrations with caution<\/li><li>Reproductive:<\/li><li>-- use caution during postpartum period as life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns; may be prevented with vitamin K administration to mother before delivery and to neonate after birth<\/li><li>-- use caution in pregnant women as prenatal exposure increases risk for congenital malformations and malignancies in newborn<\/li><li>-- pregnant women may experience increased seizure frequency<\/li><li>Other:<\/li><li>-- local or general lymphadenopathy, including lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease, has been reported and may occur with or without signs and symptoms of multiorgan hypersensitivity; long-term follow-up and use of alternative therapies recommended if occurs<\/li><li>-- acute phenytoin toxicity has been reported with serum levels sustained above optimal ranges and may result in confusional states, including delirium, encephalopathy, and psychosis or rarely irreversible cerebellar dysfunction; monitoring and dose reduction or discontinuation may be needed<\/li><li>-- elderly and gravely ill patients are at increased risk for phenytoin toxicity<\/li><li>-- acute alcohol use may increase phenytoin serum levels<\/li><li>-- chronic alcohol use may decrease phenytoin serum levels<\/li><li>-- breastfeeding not recommended since phenytoin appears to be excreted in human breast milk<\/li><li>Concomitant use:<\/li><li>-- etravirine or once-daily lopinavir-ritonavir not recommended<\/li><li>-- enteral feeding preparations not recommended<\/li><\/ul>"},{"id":"465045-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"465045-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"465045-s-4","title":"Drug Interactions","sub":[{"id":"465045-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Delavirdine (probable)<\/li><li>Isavuconazonium Sulfate (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Praziquantel (probable)<\/li><li>Ranolazine (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Telaprevir (probable)<\/li><\/ul>"},{"id":"465045-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Aluminum Carbonate, Basic (theoretical)<\/li><li>Aluminum Hydroxide (theoretical)<\/li><li>Aluminum Phosphate (theoretical)<\/li><li>Apazone (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Apremilast (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Axitinib (theoretical)<\/li><li>Beclamide (probable)<\/li><li>Bedaquiline (theoretical)<\/li><li>Blinatumomab (theoretical)<\/li><li>Bortezomib (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Cabozantinib (theoretical)<\/li><li>Calcium Carbonate (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Carbamazepine (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclophosphamide (probable)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Diazepam (probable)<\/li><li>Diazoxide (probable)<\/li><li>Dihydroxyaluminum Aminoacetate (theoretical)<\/li><li>Dihydroxyaluminum Sodium Carbonate (theoretical)<\/li><li>Dolutegravir (probable)<\/li><li>Donepezil (theoretical)<\/li><li>Dopamine (theoretical)<\/li><li>Doxorubicin (probable)<\/li><li>Doxorubicin Hydrochloride Liposome (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Edoxaban (established)<\/li><li>Eliglustat (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Ethosuximide (probable)<\/li><li>Etravirine (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Exemestane (established)<\/li><li>Ezogabine (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Fluvastatin (probable)<\/li><li>Golimumab (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Imatinib (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ixabepilone (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Ketorolac (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Ledipasvir (theoretical)<\/li><li>Lidocaine (probable)<\/li><li>Linagliptin (theoretical)<\/li><li>Lopinavir (probable)<\/li><li>Macitentan (theoretical)<\/li><li>Magaldrate (theoretical)<\/li><li>Magnesium Carbonate (theoretical)<\/li><li>Magnesium Hydroxide (theoretical)<\/li><li>Magnesium Oxide (theoretical)<\/li><li>Magnesium Trisilicate (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Miconazole (probable)<\/li><li>Mifepristone (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Netupitant (theoretical)<\/li><li>Nifedipine (probable)<\/li><li>Nilotinib (theoretical)<\/li><li>Nimodipine (probable)<\/li><li>Nintedanib (theoretical)<\/li><li>Nitisinone (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Oritavancin (theoretical)<\/li><li>Orlistat (probable)<\/li><li>Palbociclib (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (established)<\/li><li>Posaconazole (probable)<\/li><li>Regorafenib (theoretical)<\/li><li>Reserpine (theoretical)<\/li><li>Rifampin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Rocuronium (probable)<\/li><li>Roflumilast (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Secukinumab (theoretical)<\/li><li>Sertraline (probable)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sofosbuvir (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>St John's Wort (probable)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tamoxifen (probable)<\/li><li>Tasimelteon (theoretical)<\/li><li>Tegafur (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Theophylline (probable)<\/li><li>Thiotepa (probable)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tofacitinib (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><li>Voriconazole (established)<\/li><li>Vortioxetine (theoretical)<\/li><\/ul>"},{"id":"465045-s-4-15","title":"Moderate","mono":"<ul><li>Acetaminophen (probable)<\/li><li>Acetazolamide (probable)<\/li><li>Acyclovir (probable)<\/li><li>Amiodarone (probable)<\/li><li>Amitriptyline (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atorvastatin (established)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bleomycin (probable)<\/li><li>Busulfan (probable)<\/li><li>Capecitabine (probable)<\/li><li>Carboplatin (probable)<\/li><li>Caspofungin (probable)<\/li><li>Chloramphenicol (probable)<\/li><li>Cimetidine (probable)<\/li><li>Ciprofloxacin (probable)<\/li><li>Cisplatin (probable)<\/li><li>Clobazam (probable)<\/li><li>Clofazimine (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cortisone (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Desogestrel (probable)<\/li><li>Dexamethasone (established)<\/li><li>Dicumarol (probable)<\/li><li>Dienogest (probable)<\/li><li>Digitoxin (probable)<\/li><li>Diltiazem (probable)<\/li><li>Disopyramide (probable)<\/li><li>Disulfiram (probable)<\/li><li>Doxepin (probable)<\/li><li>Drospirenone (probable)<\/li><li>Estradiol Cypionate (probable)<\/li><li>Estradiol Valerate (probable)<\/li><li>Ethinyl Estradiol (probable)<\/li><li>Ethynodiol Diacetate (probable)<\/li><li>Etonogestrel (probable)<\/li><li>Felbamate (probable)<\/li><li>Fluconazole (probable)<\/li><li>Fludrocortisone (probable)<\/li><li>Fluorouracil (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fluvoxamine (probable)<\/li><li>Folic Acid (probable)<\/li><li>Fosamprenavir (probable)<\/li><li>Gefitinib (probable)<\/li><li>Ginkgo (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Imipramine (probable)<\/li><li>Isoniazid (probable)<\/li><li>Levodopa (probable)<\/li><li>Levomethadyl (probable)<\/li><li>Levonorgestrel (probable)<\/li><li>Levothyroxine (probable)<\/li><li>Medroxyprogesterone Acetate (probable)<\/li><li>Meperidine (probable)<\/li><li>Mestranol (probable)<\/li><li>Methoxsalen (probable)<\/li><li>Methsuximide (probable)<\/li><li>Midazolam (probable)<\/li><li>Nafimidone (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Nilutamide (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Norelgestromin (probable)<\/li><li>Norethindrone (probable)<\/li><li>Norgestimate (probable)<\/li><li>Norgestrel (probable)<\/li><li>Ospemifene (established)<\/li><li>Oxcarbazepine (probable)<\/li><li>Paclitaxel (probable)<\/li><li>Pancuronium (probable)<\/li><li>Paroxetine (probable)<\/li><li>Phenprocoumon (probable)<\/li><li>Piperine (probable)<\/li><li>Prednisolone (probable)<\/li><li>Prednisone (probable)<\/li><li>Progabide (probable)<\/li><li>Quetiapine (established)<\/li><li>Quinidine (probable)<\/li><li>Quinine (probable)<\/li><li>Remacemide (probable)<\/li><li>Rifapentine (probable)<\/li><li>Risperidone (probable)<\/li><li>Rufinamide (probable)<\/li><li>Sabeluzole (probable)<\/li><li>Shankhapulshpi (probable)<\/li><li>Simvastatin (probable)<\/li><li>Sirolimus (probable)<\/li><li>Sulfamethizole (probable)<\/li><li>Sulfamethoxazole (probable)<\/li><li>Sulfaphenazole (probable)<\/li><li>Sulthiame (probable)<\/li><li>Telithromycin (probable)<\/li><li>Tenidap (probable)<\/li><li>Tiagabine (probable)<\/li><li>Ticlopidine (probable)<\/li><li>Ticrynafen (probable)<\/li><li>Tirilazad (probable)<\/li><li>Tizanidine (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Topiramate (probable)<\/li><li>Trazodone (probable)<\/li><li>Triamcinolone (probable)<\/li><li>Trimethoprim (probable)<\/li><li>Tubocurarine (probable)<\/li><li>Valproic Acid (probable)<\/li><li>Vecuronium (probable)<\/li><li>Verapamil (probable)<\/li><li>Vigabatrin (probable)<\/li><li>Viloxazine (probable)<\/li><\/ul>"}]},"5":{"id":"465045-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Morbilliform eruption, Rash (5% to 10%)<\/li><li><b>Gastrointestinal:<\/b>Constipation, Gingival enlargement, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Ataxia, Coordination problem, Nystagmus, Slurred speech<\/li><li><b>Psychiatric:<\/b>Confusion, Feeling nervous<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Bullous dermatosis (Rare), Erythroderma (Rare), Lupus erythematosus, Purpuric rash (Rare), Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Granulocytopenic disorder, Leukopenia, Myelosuppression, Pancytopenia, Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Hepatotoxicity, Liver damage, Toxic hepatitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Anticonvulsant hypersensitivity syndrome (0.01% to 0.1%), Systemic lupus erythematosus<\/li><li><b>Psychiatric:<\/b>Suicidal thoughts<\/li><li><b>Renal:<\/b>Nephrotoxicity<\/li><li><b>Other:<\/b>Drug withdrawal seizure<\/li><\/ul>"},"6":{"id":"465045-s-6","title":"Drug Name Info","sub":{"0":{"id":"465045-s-6-17","title":"US Trade Names","mono":"<ul><li>Dilantin<\/li><li>Dilantin Infatabs<\/li><li>Dilantin-125<\/li><\/ul>"},"2":{"id":"465045-s-6-19","title":"Class","mono":"<ul><li>Anticonvulsant<\/li><li>Hydantoin (class)<\/li><\/ul>"},"3":{"id":"465045-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"465045-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"465045-s-7","title":"Mechanism Of Action","mono":"Phenytoin is an antiepileptic drug that possibly enhances sodium efflux from neurons of the motor cortex. This cellular event tends to stabilize the threshold against hyperexcitability that results from excessive stimulation or environmental changes capable of reducing membrane sodium gradient. Posttetanic potentiation at synapses is then reduced preventing cortical seizure foci from detonating adjacent cortical areas.<br\/>"},"8":{"id":"465045-s-8","title":"Pharmacokinetics","sub":[{"id":"465045-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1.5 to 3 hours<\/li><li>Bioavailability, Oral: 20% to 90%<\/li><li>Effect of food: increased absorption<\/li><\/ul>"},{"id":"465045-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: highly bound<\/li><li>Vd: 0.5 to 1.0 L\/kg<\/li><\/ul>"},{"id":"465045-s-8-25","title":"Metabolism","mono":"Hepatic; hydroxylation <br\/>"},{"id":"465045-s-8-26","title":"Excretion","mono":"<ul><li>Bile: extensive<\/li><li>Renal: excreted in urine after reabsorbtion from intestinal tract<\/li><li>Dialyzable: Yes (hemodialysis), 41.3%; No (peritoneal)<\/li><li>Total body clearance: decreased in elderly patients<\/li><\/ul>"},{"id":"465045-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Chewable tablet, 14 hr<\/li><li>Suspension, 22 hr<\/li><\/ul>"}]},"9":{"id":"465045-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>(suspension) shake well before measuring dose <br\/>"},"10":{"id":"465045-s-10","title":"Monitoring","mono":"<ul><li>seizure control is indicative of efficacy<\/li><li>phenytoin serum levels; (usual range 10 to 20 mcg\/mL) to achieve optimal dosage adjustments and establish maintenance doses, when switching a patient from the sodium salt to the free acid form and vice versa, or at first sign of acute toxicity (eg, confusion, delirium, psychosis, encephalopathy)<\/li><li>phenytoin serum levels; obtain at least 5 to 7 half-lives (at least 7 to 10 days) after treatment initiation, dosage change, or addition or subtraction of another drug to the regimen<\/li><li>phenytoin serum levels; obtain more frequently in patients receiving enteral feedings and\/or nutritional supplements<\/li><li>emergence or worsening of depression, suicidal thoughts or behavior, and\/or any unusual changes in mood or behavior<\/li><\/ul>"},"11":{"id":"465045-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Suspension: 125 MG\/5 ML<\/li><li>Oral Tablet, Chewable: 50 MG<\/li><\/ul><\/li><li><b>Dilantin-125<\/b><br\/>Oral Suspension: 125 MG\/5 ML<br\/><\/li><li><b>Dilantin Infatabs<\/b><br\/>Oral Tablet, Chewable: 50 MG<br\/><\/li><\/ul>"},"12":{"id":"465045-s-12","title":"Toxicology","sub":[{"id":"465045-s-12-31","title":"Clinical Effects","mono":"<b>PHENYTOIN <\/b><br\/>This management includes phenytoin and ethotoin, both in the hydantoin class of anticonvulsants; however, phenytoin will be the primary drug discussed. Fosphenytoin is covered in a separate management. USES: Phenytoin is primarily used as an anticonvulsant, both for status epilepticus and for seizure prevention. PHARMACOLOGY: Phenytoin stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during nerve impulse generation. TOXICOLOGY: Phenytoin prolongs effective refractory period and suppresses ventricular pacemaker automaticity, thus shortening the action potential in the heart. The intravenous form of phenytoin is dissolved in 40% propylene glycol and 10% ethanol at a pH of 12. This formulation can have its own toxicity secondary to cardiac toxicity of propylene glycol (mechanism unknown) and tissue necrosis from infiltration (secondary to the alkaline nature of the formulation). EPIDEMIOLOGY: There are thousands of exposures reported to poison centers every year, as it is a widely used anticonvulsant. However, deaths are extremely rare and severe manifestations occur in only a minority of cases. MILD TO MODERATE TOXICITY: Nausea and vomiting may develop early after overdose. Nystagmus, ataxia, and mild CNS depression are common. SEVERE TOXICITY: Large oral ingestions can cause more severe CNS depression, coma, and, rarely, respiratory depression. Rapid infusion of the parenteral formulation (faster than 50 mg\/min) can cause hypotension, bradycardia, AV conduction delays, and ventricular dysrhythmias which may be fatal. It is felt that the cardiotoxicity of the intravenous formulation of phenytoin is secondary to the diluent, propylene glycol, and not the phenytoin itself. ADVERSE EFFECTS: Significant adverse effects seen from intravenous use of phenytoin include venous irritation and pain, and thrombophlebitis. Extravasation can cause tissue necrosis. Adverse effects unrelated to plasma phenytoin levels include hypertrichosis, gingival hypertrophy, thickening of facial features, carbohydrate intolerance, folic acid deficiency, peripheral neuropathy, vitamin D deficiency, osteomalacia, and systemic lupus erythematosus (SLE). Some rarely seen but important adverse reactions include blood dyscrasias, dyskinesias, hepatitis, lymphadenopathy, lymphoma, pseudolymphoma, SLE-like syndrome, Steven-Johnson Syndrome, and toxic epidermal necrolysis. Phenytoin is a known teratogen. Fetal hydantoin syndrome is characterized by microcephaly, mental retardation, craniofacial abnormalities, and digital hypoplasia. It occurs in 10% to 30% of exposed pregnancies.<br\/>"},{"id":"465045-s-12-32","title":"Treatment","mono":"<b>PHENYTOIN <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: For mild and moderate toxicity, treat with supportive care, as the patient eventually metabolizes the phenytoin. If the patient is awake and alert, administer a dose of activated charcoal. Protect the patient from self-injury secondary to ataxia. MANAGEMENT OF SEVERE TOXICITY: For large phenytoin overdoses, treat with supportive care, which may include intubation for comatose patients. If seizures do occur, treat with benzodiazepines and evaluate for other causes of seizures. PARENTERAL EXPOSURE: In patients with parenteral overdoses, monitor mental status and intubate patients with significant CNS depression. Treat hypotension with intravenous fluids, add vasopressors if hypotension persists. Treat dysrhythmias with standard ACLS protocols. Thrombophlebitis and infiltrations should be treated supportively with pain medications such as NSAIDs and warm compresses.<\/li><li>Decontamination: PREHOSPITAL: Prehospital activated charcoal might be considered if the patient is awake, alert, and cooperative, and the exposure was relatively recent (within the last hour). HOSPITAL: Activated charcoal could be considered if the patient is awake, alert, and cooperative, and the ingestions is relatively recent. Gastric lavage should be avoided in most phenytoin overdoses as it is not life-threatening.<\/li><li>Airway management: Perform endotracheal intubation in patients with significant CNS depression.<\/li><li>Antidote: None<\/li><li>Extravasation injury: If extravasation occurs, stop the infusion. Disconnect the IV tubing, but leave the cannula or needle in place. Attempt to aspirate the extravasated drug from the needle or cannula. If possible, withdraw 3 to 5 mL of blood and\/or fluids through the needle\/cannula. Administer hyaluronidase. Elevate the affected area. Apply a warm or cold compress as indicated. One study recommended applying a dry warm compress. However, another source recommended ice packs for 15 to 20 minutes at least 4 times daily. Administer analgesics for severe pain. If pain persists, there is concern for compartment syndrome, or injury is apparent, an early surgical consult should be considered. Close observation of the extravasated area is suggested.  If tissue sloughing, necrosis or blistering occurs, treat as a chemical burn (ie, antiseptic dressings, silver sulfadiazine, antibiotics when applicable).  Surgical or enzymatic debridement may be required. Risk of infection is increased in chemotherapy patients with reduced neutrophil count following extravasation. Consider culturing any open wounds. Monitor the site for the development of cellulitis, which may require antibiotic therapy.<\/li><li>Monitoring of patient: Obtain a basic metabolic panel, aspirin concentration, and acetaminophen concentration after deliberate overdose. Monitor phenytoin concentrations every 4 hours until clearly declining.  Monitor serial neurologic examinations. Obtain an ECG and institute continuous cardiac monitoring during and after rapid intravenous infusion or intravenous overdose. Obtain serum albumin concentration as phenytoin toxicity may occur in the setting of normal total serum phenytoin concentrations, but elevated free phenytoin concentrations. Some clinical effects reported in elevated phenytoin concentrations include: greater than 20 mcg\/mL: far lateral nystagmus; greater than 30 mcg\/mL: 45 degrees lateral gaze nystagmus and ataxia; greater than 40 mcg\/mL: decreased mentation; greater than 100 mcg\/mL: death.<\/li><li>Enhanced elimination procedure: There is some evidence that repeated doses of charcoal may enhance phenytoin elimination, but the evidence is weak that actually improves outcomes, and it should not be given in drowsy patients secondary to the risk of aspiration pneumonitis, so it is rarely indicated. Although there are some anecdotal reports of efficacy, there is no indication for hemodialysis, hemoperfusion, or urinary alkalinization.<\/li><li>Patient disposition: HOME CRITERIA: For unintentional ingestions where the patient is asymptomatic and the dose is less than 20 mg\/kg, the patient can be observed at home. OBSERVATION CRITERIA: Any intentional overdose or inadvertent overdoses above 20 mg\/kg, or if symptomatic, the patient should be sent to a healthcare facility for observation. Patients should be observed for at least 4 to 6 hours, and should not be sent home until symptoms are clearly improving, or they are asymptomatic and serum concentrations are clearly declining. ADMISSION CRITERIA: Patients who have worsening symptoms after 4 to 6 hours or with significant ataxia or CNS depression, and those with rising serum concentrations, should be admitted to the hospital. If the CNS depression is severe enough that there is respiratory depression or concern of airway protection, the patient should be admitted to an intensive care setting. Otherwise, most patients can be safely admitted to a hospital ward bed. Criteria for discharge from the hospital should include clinical symptomatic improvement, which should be reflected by declining phenytoin serum concentrations. CONSULT CRITERIA: In patients with cardiac toxicity secondary to the intravenous formulation of phenytoin, it might be reasonable to consult a cardiologist. Neurologists are often very familiar with both the acute and chronic toxicity of phenytoin. Consult a medical toxicologist or poison center for patients with severe toxicity.<\/li><\/ul>"},{"id":"465045-s-12-33","title":"Range of Toxicity","mono":"<b>PHENYTOIN<\/b><br\/>TOXICITY: The minimum acute toxic oral overdose is 20 mg\/kg. However, since phenytoin has dose-dependent kinetics, inadvertent intoxication from drug interactions or small dose adjustments can easily occur in patients taking the medication chronically. Fatalities have most often been associated with the intravenous formulation being given too rapidly, and is thought to be secondary to the propylene glycol diluent rather than the phenytoin itself. THERAPEUTIC DOSE: SEIZURE DISORDER: ADULT: Usual maintenance dose is 100 mg orally 3 to 4 times daily, up to a maximum of 600 mg\/day. PEDIATRIC: Children less than 6 years of age: 5 mg\/kg\/day divided into 2 or 3 doses up to a maximum of 300 mg\/day; usual maintenance dose is 4 to 8 mg\/kg\/day. Children older than 6 years of age: May require the minimum adult dose of 300 mg\/day. STATUS EPILEPTICUS: ADULT: Loading dose is between 10 to 15 mg\/kg IV with a maximum rate of 50 mg\/minute. PEDIATRIC: The recommended loading dose is 15 to 20 mg\/kg IV at a rate not exceeding 1 to 3 mg\/kg\/min or 50 mg\/min (whichever is slower).<br\/>"}]},"13":{"id":"465045-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness, drowsiness, or confusion.<\/li><li>This drug may decrease effectiveness of oral contraceptives with concurrent use. Recommend additional form of birth control.<\/li><li>This drug may cause constipation, gingival hyperplasia, nausea, vomiting, ataxia, choreoathetosis, coordination problems, insomnia, paresthesia, slurred speech, and nervousness.<\/li><li>Tell patient to report signs\/symptoms of pancytopenia, nephrotoxicity, hepatotoxicity, or systemic lupus erythematosus (arthralgias, myalgias, fatigue, skin rashes).<\/li><li>Patient should report signs\/symptoms of a severe skin reaction such as Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering) or toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li> Drug may cause hyperglycemia. Advise patients with diabetes to carefully monitor blood sugar levels more often.<\/li><li>Advise patient against sudden discontinuation of drug, as this may precipitate status epilepticus.<\/li><li>Patient should take with food to minimize gastric irritation. If taking drug in a tube feeding, take drug at least 2 h before or 2 h after tube feeding.<\/li><li>Wait at least 1 h after taking drug before using any antacids.<\/li><li>Patient should not drink alcohol while taking this drug, as this may affect the blood level of phenytoin.<\/li><\/ul>"}}}